Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will ...

South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Samsung Biologics spins off Samsung Bioepis Holdings to enhance competitiveness Samsung Bioepis Holdings aims to streamline ...

Samsung Biologics announced on May 22 that it will spin off its biosimilar unit, Samsung Bioepis, to create a new holding ...

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

SEOUL ― South Korean drugmaker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies to help allay customer concerns about conflicts ...

Samsung Biologics, the biotech arm of Samsung Group, announced Thursday that it will spin off its biosimilar operations into ...

Samsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines ...

The biotech arm of South Korea’s Samsung Group, Samsung Biologics, has four manufacturing plants in the region. During Samsung Biologics’ Q1 financial call, CEO John Rim confirmed that the firm had ...